D-1300-2022 Class II Terminated
FDA drug recall D-1300-2022 was initiated by Tolmar, Inc. on Jul 11, 2022 and is designated Class II. Reason for recall: Failed Impurities/ degradation specifications: Out-of-Specification test results obtained for Unspecified Impurity Relative Retention Time The recall status is terminated (terminated Jun 22, 2023). Affected quantity: 1271 tubes.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 10, 2022
- Initiation Date
- Jul 11, 2022
- Termination Date
- Jun 22, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1271 tubes
Product description
Naftifine Hydrochloride Gel, USP 1%, packaged in cartons with: a) Net Wt. 90g tube (NDC 0115-1510-48), b) Net Wt. 40g tube (NDC 0115-1510-63), c) Net Wt. 60g tube (NDC 0115-1510-58), Rx only, Manufactured by: Tolmar, Inc., Fort Collins, CO, 80526, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807
Reason for recall
Failed Impurities/ degradation specifications: Out-of-Specification test results obtained for Unspecified Impurity Relative Retention Time
Distribution pattern
distributed to 1 consignee in KY.
Code information
Lot #: a) 12070A, Exp 5/2023; 11801A, Exp 9/2022; b) 12386A, Exp 8/2023; 11800A, Exp 9/2022; c) 11940A, Exp 12/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1300-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026